Partner with us
Home/News/Press Releases

Press Releases

Official announcements from Fedora Pharmaceuticals — from landmark licensing deals to the latest data on FPI-2119.

June 3, 2026
FPI-2119 Takes Center Stage at ESCMID Global 2026
May 12, 2026
Presentations at 2026 ESCMID Highlight Safety and Potent Bactericidal Activity of FPI-2119
May 12, 2026
Fedora Showcasing Its Antibiotic Candidate at the 2026 ESCMID Congress
March 13, 2026
Investigational Antibiotic Shows Broad Activity Against Resistant Gram-Negative Pathogens
January 29, 2026
Fedora Highlights Efficacy of FPI-2119 Against Resistant Gram-Negative Bacteria at IMARI 2026
January 13, 2026
Fedora Re-emerges to Unveil a Novel Class of Antibiotics at IMARI 2026
November 24, 2020
Leading Biomedical & Research Groups Launch Coalition Against AMR
June 8, 2018
Canadian Declaration on Antimicrobial Resistance
January 16, 2017
Fedora Receives Support from the Government of Canada to Battle AMR
February 10, 2016
Super Drugs for Superbugs: Edmonton Firm Wins Largest Biotech Licensing Deal in Canadian History
January 5, 2016
Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating AMR
November 30, 2015
Fedora Receives Alberta Life Sciences “Company of the Year” Award
November 9, 2015
Fedora Receives 2015 ASTech Award for Outstanding Commercial Achievement
January 13, 2015
Roche, Meiji and Fedora Join Forces to Tackle Bacterial Resistance to Antibiotics
September 12, 2013
FPI-1465 Increases Activity of Certain Antibiotics Against Drug-Resistant Bacteria
October 31, 2012
Fedora Appoints Ronald Odynski and Dr. Leonard Post to Board of Directors
September 5, 2012
Fedora Appoints Thomas R. Parr, Ph.D., Chief Scientific Officer
Designed by Gravitas Digital in partnership with